<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911011-0191</DOCNO><DOCID>911011-0191.</DOCID><HL>   Ex-Bolar Officials   Are Charged by FDA   In Generic Drug Case</HL><DATE>10/11/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B2</SO><CO>   BLR</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DRUG MANUFACTURERS (DRG)</IN><GV>FOOD AND DRUG ADMINISTRATION (FDA)JUSTICE DEPARTMENT (JUS)</GV><RE>MARYLAND (MD)NORTH AMERICA (NME)NEW YORK (NY)UNITED STATES (US)</RE><LP>   BALTIMORE -- Four former high-ranking officials of BolarPharmaceutical Co. were charged in what federal prosecutorssaid was the culmination of its investigation into thecompany's illegal activities involving a hypertensionmedicine.   In early 1990, the Food and Drug Administration withdrewits approval of Bolar's generic formulation of Dyazide afterinvestigators discovered the drug was not a genericformulation but the branded drug made by SmithKline BeechamCorp. of Philadelphia. Since then, the Copiague, N.Y.,concern has pleaded guilty, settled a suit filed bySmithKline and paid $10 million in fines.</LP><TEXT>   In the latest actions, Robert Shulman, 58 years old,former president and chief executive officer, was charged ina criminal information filed by prosecutors with conspiracy,wire fraud, making false statements to the FDA, andobstructing an FDA investigation. Prosecutors said Mr.Shulman is cooperating with the government. Mr. Shulmancouldn't be reached for comment.   In addition, a federal grand jury indicted Jacob H.Rivers, 62, former executive vice president and director;Charles G. Dicola, 41, former vice president of operations;and Arnold S. Mendell, 47, former director of qualityassurance. All were charged with similar counts ofconspiracy, fraud, obstruction and false statements. Allthree men declined to comment.   The U.S. Attorney's office in Baltimore, which has beeninvestigating the case, said all of the defendants had workedto obstruct both the FDA's regulatory authority over thedrug-approval process, and its investigation when it latersuspected wrongdoing at Bolar. Further, they lied toinvestigators, and fabricated, concealed or destroyeddocuments, including deletion of data from company computerfiles, in order to cover up the use of Dyazide as its owngeneric equivalent, the U.S. attorney's office said.   Prosecutors said arraignment dates for the four defendantshaven't been set yet.</TEXT></DOC>